Patents by Inventor Anthony Varca

Anthony Varca has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ELECTRONIC PULSE INJECTION SYSTEM FOR AN ICING WIND TUNNEL
    Publication number: 20240094085
    Abstract: A system is provided for dispersing supercooled liquid water in an icing wind tunnel. The system includes a spray bar; a spray nozzle coupled to the spray bar; a pressure control valve coupled to the spray bar; and a controller coupled to the pressure control valve and the spray nozzle. The controller is configured to receive input identifying a selected liquid water content and a selected water droplet size for dispersing the supercooled liquid water in the icing wind tunnel; configure an injector duty cycle of the spray nozzle to generate the selected liquid water content; and configure the pressure control valve to generate the selected water droplet size, wherein configuring the spray nozzle and the pressure control valve disperses the supercooled liquid water in the icing wind tunnel.
    Type: Application
    Filed: September 16, 2022
    Publication date: March 21, 2024
    Applicant: GOODRICH CORPORATION
    Inventors: Richard J. Carpino, II, Anthony Varca, Matthew Hamman
  • FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28
    Publication number: 20230365583
    Abstract: The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof. The present disclosure further relates to methods of treating a disease or disorder associated with ubiquitin-specific protease 28 (USP28) and methods of inhibiting USP28.
    Type: Application
    Filed: August 10, 2021
    Publication date: November 16, 2023
    Inventors: Sara Buhrlage, Anthony Varca, Bin Hu
  • SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28
    Publication number: 20230271918
    Abstract: The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof and pharmaceutical composition comprising the compound of formula (I). The present composition also relates to methods treating a disease or disorder associated with ubiquitin-specific protease 28 (USP28), methods of treating cancer, and methods of inhibiting USP28.
    Type: Application
    Filed: August 10, 2021
    Publication date: August 31, 2023
    Inventors: Sara Buhrlage, Anthony Varca, Bin Hu
  • SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28
    Publication number: 20230265082
    Abstract: The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, and to a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier. The disclosure also relates to a method of treating a disease or disorder associated with ubiquitin-specific protease 28 (USP28) a method of treating cancer, and a method of inhibiting USP28, comprising administering to a subject in need thereof a compound of formula (I).
    Type: Application
    Filed: August 10, 2021
    Publication date: August 24, 2023
    Inventors: Sara Buhrlage, Anthony Varca, Bin Hu
  • SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF
    Publication number: 20230115483
    Abstract: Provided herein are compounds that interrupt the function of SALL4. Also described are pharmaceutical compositions and medical uses of these compounds.
    Type: Application
    Filed: November 1, 2022
    Publication date: April 13, 2023
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Jun Qi, Anthony Varca, Li Chai
  • Small molecule inhibition of transcription factor SALL4 and uses thereof
    Patent number: 11530209
    Abstract: Provided herein are compounds that interrupt the function of SALL4. Also described are pharmaceutical compositions and medical uses of these compounds.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: December 20, 2022
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Jun Qi, Anthony Varca, Li Chai
  • SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF
    Publication number: 20200317664
    Abstract: Provided herein are compounds that interrupt the function of SALL4. Also described are pharmaceutical compositions and medical uses of these compounds.
    Type: Application
    Filed: October 4, 2018
    Publication date: October 8, 2020
    Inventors: Jun Qi, Anthony Varca, Li Chai
  • CHROMOBOX PROTEIN INHIBITORS AND USES THEREOF
    Publication number: 20200024267
    Abstract: Provided herein are compounds useful as inhibitors of CBX. Also described are pharmaceutical compositions and medical uses of these compounds.
    Type: Application
    Filed: September 25, 2017
    Publication date: January 23, 2020
    Inventors: James Bradner, Jun Qi, Alexander Federation, Zoe Jacobson, Anthony Varca
  • Folate-conjugated molecules for delivery of toxic small molecule inhibitors to cancer cells and methods of use
    Patent number: 10525139
    Abstract: The invention relates to novel derivatives of thapsigargin that are chemically modified with a group that targets a cell surface-expressed receptor, and pharmaceutical preparations thereof. The invention further relates to methods of treating diseases such as cancer using the compounds of the invention.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: January 7, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: James Bradner, Kimberly Stegmaier, Jun Qi, Anthony Varca, Giovanni Roti
  • FOLATE-CONJUGATED MOLECULES FOR DELIVERY OF TOXIC SMALL MOLECULE INHIBITORS TO CANCER CELLS AND METHODS OF USE
    Publication number: 20180280522
    Abstract: The invention relates to novel derivatives of thapsigargin that are chemically modified with a group that targets a cell surface-expressed receptor, and pharmaceutical preparations thereof. The invention further relates to methods of treating diseases such as cancer using the compounds of the invention.
    Type: Application
    Filed: November 5, 2015
    Publication date: October 4, 2018
    Inventors: James Bradner, Kimberly Stegmaier, Jun Qi, Anthony Varca, Giovanni Roti